Sangamo seeks MHRA authorization for CTA for Phase 1/2 Clinical Trial assessing SB-FIX
Sangamo Therapeutics declared that the Medicines and Healthcare Products Regulatory Agency of the United Kingdom has extended Clinical Trial Authorization for enlisting subjects into…
Read More...
Read More...